Ticagrelor for preventing atherothrombotic events after myocardial infarction
KEYWORDS: ticagrelor, committee, treatment, myocardial, infarction, myocardial infarction, risk, company, clinical, atherothrombotic, patients, therapy, aspirin, considered, events

and are at increased risk of atherothrombotic events. The committee was aware that the company's rationale for the narrower population was that the marketing authorisation focuses on those patients for whom the adverse effect profile was most favourable in PEGASUS-TIMI 54. The marketing authorisation allows ticagrelor to be started in patients 1 to 2 years after a myocardial infarction or within 1 year of stopping treatment with a previous antiplatelet therapy. Based on clinical practice in England, the company suggested that few patients would have stopped antiplatelet therapy within 1 year. However, the committee noted comments received during consultation that the full population covered by the marketing authorisation should be included in the committee's discussions; that is, not only people who had a myocardial infarction 1 to 2 years ago, but also people who had a myocardial infarction more than 2 years ago and stopped taking antiplatelet therapy no more than 1 year ago. The committee considered that because this latter group is covered by the marketing authorisation, and given comments that ticagrelor would be valued as an option for these people, it should include this group. The committee further concluded that although there may be only a minority of
